Skip to main content

Table 2 Univariate and multivariate Cox regression models in the propensity score-matched cohort

From: Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study

 

Univariate

Multivariate

 
 

HR (95% CI)

P-value

HR (95% CI)

P-value

Group

    

 PCT + RT vs. PCT + CCRT

0.67 (0.46–0.97)

0.036

0.59 (0.39–0.88)

0.009

Age (years)

    

  < 45 vs. ≥ 45

1.18 (0.81–1.72)

0.389

  

Sex

    

 Male vs. Female

0.53 (0.28–1.00)

0.054

0.50 (0.27–0.94)

0.033

Diagnosis period

    

 2000–2005 vs. 2006–2011

0.52 (0.30–0.92)

0.025

  

 2000–2005 vs. 2012–2017

0.46 (0.27–0.77)

0.003

  

Pathology

    

 I-II vs. III

0.78 (0.58–1.04)

0.093

  

Tumor category

    

 T1-2 vs. T3-4

1.06 (0.61–1.83)

0.834

  

Node category

    

 N0-1 vs. N2-3

1.10 (0.71–1.71)

0.670

  

Bone metastasis

    

 Absent vs. Single

0.66 (0.39–1.11)

0.117

  

 Absent vs. Multiple

1.77 (0.87–2.12)

0.177

  

Liver metastasis

    

 Absent vs. Single

0.83 (0.40–1.71)

0.606

1.06 (0.51–2.22)

0.871

 Absent vs. Multiple

2.32 (1.38–3.88)

0.001

1.95 (1.13–3.35)

0.016

Lung metastasis

    

 Absent vs. Single

0.79 (0.38–1.62)

0.514

  

 Absent vs. Multiple

1.32 (0.74–2.37)

0.346

  

Distant nodal metastasis

    

 Absent vs. Present

1.53 (0.92–2.55)

0.100

  

No. of metastatic organs

    

 Single organ vs. Multiple organs

1.62 (0.98–2.66)

0.059

  

Metastatic situation

    

 Organ metastasis without LN involvement vs. Organ metastasis with LN involvement

1.26 (0.94–1.69)

0.116

  

No. of metastatic lesions

    

 Oligo vs. Multiple

2.18 (1.42–3.34)

 < 0.001

1.97 (1.23–3.16)

0.005

PCT regimen

    

 PF vs. TP

1.21 (0.77–1.91)

0.415

  

 PF vs. TPF

0.65 (0.40–1.05)

0.077

  

No. of PCT cycles

    

 1–3 vs. 4–6

0.61 (0.40–0.92)

0.020

0.49 (0.31–0.77)

0.002

 1–3 vs. > 6

0.47 (0.18–1.22)

0.120

0.27 (0.09–0.77)

0.014

Response to PCT

    

 CR/PR vs. SD

1.19 (0.93–1.53)

0.159

  

KPS before RT

    

 90 vs. 70–80

1.30 (0.69–2.42)

0.417

  

Technique of RT

    

 Conventional RT vs. IMRT

0.74 (0.49–1.13)

0.162

  

Local treatment of metastatic sites

    

 No vs. Yes

0.65 (0.44–0.98)

0.040

0.69 (0.45–1.05)

0.082

  1. PCT palliative chemotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy, HR hazard ratio, CI confidence interval, No. number, LN lymph node, PF cisplatin plus 5-fluorouracil, TP cisplatin plus docetaxel, TPF cisplatin plus docetaxel plus 5-fluorouracil, CR complete response, PR partial response, SD stable disease, KPS Karnofsky performance score, IMRT intensity-modulated radiotherapy
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us